1. Home
  2. Our Firm
  3. News
  4. Guggenheim Securities Hires Robert Arsov as Managing Director, Technology Investment Banking

Our Firm

June 04, 2014

Guggenheim Securities Hires Robert Arsov as Managing Director, Technology Investment Banking

NEW YORK – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, today announced the hiring of Robert Arsov as a Managing Director. Mr. Arsov will focus on advising companies across the technology industry as well as other growth sectors such as IT/business services.

The addition of Mr. Arsov broadens the reach of Guggenheim Securities' full-service investment banking capabilities dedicated to the dynamic and fast-growing technology sector.

"We are very pleased to welcome Robert to the team," said Mark Van Lith, Head of Investment Banking at Guggenheim Securities. "Robert's strong relationships, M&A expertise and insights and global perspective on the technology industry complement our strong TMT investment banking effort."

“I’m truly excited to join Guggenheim Securities and its clients-first culture,” said Mr. Arsov. “I look forward to contributing to the growth of the firm’s full service investment banking business in the technology sector.”

Mr. Arsov has worked on strategic transactions and financings with some of the most notable companies in the technology, IT/business services and biotech sectors, including Accenture, Bayer, Coriant, CSC, Ericsson, Fiserv, Genzyme, Genstar Partners, Intuit, Liberty Global, Marlin Equity Partners, Mylan, Nokia, NSN, Royalty Pharma, Stone Point and Xerox. Mr. Arsov was previously a member of the Mergers & Acquisitions Group at Credit Suisse and its predecessor company Donaldson, Lufkin & Jenrette, in New York.

A Macedonia native, he is a vice chairman and a director of Macedonia 2025, an organization aiming to improve the country’s economic and democratic development.

Mr. Arsov holds a B.S. degree from the Walter A. Haas School of Business at the University of California, Berkeley.


About Guggenheim Partners

Guggenheim Partners is a global investment and advisory firm with more than $210 billion in assets under management. The firm provides asset management, investment banking and capital markets services, insurance services, institutional finance and investment advisory solutions to institutions, governments and agencies, corporations, investment advisors, family offices and individuals. Guggenheim Partners is headquartered in New York and Chicago and serves clients around the world from more than 25 offices in eight countries. For more information about Guggenheim Partners, visit www.guggenheimpartners.com.


Media Contacts

Thomas S. Mulligan
Sitrick And Company
310.367.6567
thomas_mulligan@sitrick.com

Terry Fahn
Sitrick And Company
310.788.2850
terry_fahn@sitrick.com



November 09, 2020

Guggenheim Securities Hires David Levin to Expand Equity Capital Markets

NEW YORK, NY –  Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that David Levin will join the firm as a Senior Managing Director in Equity Capital Markets, focusing on providing clients with equity and equity-linked financing solutions through the public and alternative equity capital markets.

Read More

October 22, 2020

Guggenheim Securities Hires Joe Niemiec to Expand Middle Market Investment Banking Practice

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Joe Niemiec has joined the firm as a Senior Managing Director to expand its middle market investment banking coverage and to focus on advising companies in the services and industrials sectors.

Read More

October 05, 2020

Debjit Chattopadhyay Joins Guggenheim Securities as Senior Biotech Analyst

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Debjit Chattopadhyay will join the firm in December as a Managing Director and Senior Biotech Analyst as part of the Healthcare Equity Research team. Dr. Chattopadhyay’s research focus will be gene therapy and rare diseases.

Read More



© 2020 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and Innovative Solutions. Enduring Values. are registered trademarks of Guggenheim Capital, LLC.